Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.
BACKGROUND: Alemtuzumab (MabCampath or Campath; Genzyme, Cambridge, MA) is a CD52-specific monoclonal antibody that causes profound and sustained lymphocyte depletion. Its use as an induction therapy in organ transplantation is increasing. Since our last systematic review in 2006, where we identifi...
Autors principals: | Morgan, R, O'Callaghan, J, Knight, SR, Morris, P |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
2012
|
Ítems similars
-
Systematic reviews of alemtuzumab in renal transplantation.
per: O'Callaghan, J, et al.
Publicat: (2013) -
Systematic reviews of alemtuzumab in renal transplantation
per: O'Callaghan, J, et al.
Publicat: (2013) -
Systematic review and meta-analysis of hypothermic machine perfusion versus static cold storage of kidney allografts on transplant outcomes.
per: O'Callaghan, J, et al.
Publicat: (2013) -
Preservation solutions for static cold storage of kidney allografts: A systematic review and meta-analysis
per: O'Callaghan, J, et al.
Publicat: (2012) -
Preservation solutions for static cold storage of kidney allografts: a systematic review and meta-analysis.
per: O'Callaghan, J, et al.
Publicat: (2012)